ArticleMultiple sclerosis (Houndmills, Basingstoke, England)2019
Predicting the profile of increasing disability in multiple sclerosis.
Article in Multiple sclerosis (Houndmills, Basingstoke, England), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Predictive factors for the progression of multiple sclerosis: a meta-analysis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025Pooled it
- Rituximab in secondary progressive multiple sclerosis: a meta-analysis.Annals of clinical and translational neurology · 2024Pooled it
- Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: Data from the OPERA I and OPERA II trials.European journal of neurology · 2022Trial
- Factors associated with the progression of disability (EDSS) among MS patients.eNeurologicalSci · 2026Article
- The Utility of Intravoxel Incoherent Motion Metrics in Assessing Disability in Relapsing-Remitting Multiple Sclerosis.Diagnostics (Basel, Switzerland) · 2025Article
- Choosing initial MS therapy; personal, disease, and medication factors.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025Review
- Prognostic models for predicting clinical disease progression, worsening and activity in people with multiple sclerosis.The Cochrane database of systematic reviews · 2023Review
- Diagnosis and treatment of progressive multiple sclerosis: A position paper.European journal of neurology · 2023Review
- Similarities and differences between multiple sclerosis and type 1 diabetes.Diabetes/metabolism research and reviews · 2022Article
- Prognostic Accuracy of NEDA-3 in Long-term Outcomes of Multiple Sclerosis.Neurology(R) neuroimmunology & neuroinflammation · 2021Article
- Predictors of training-related improvement in visuomotor performance in patients with multiple sclerosis: A behavioural and MRI study.Multiple sclerosis (Houndmills, Basingstoke, England) · 2021Article
- Early High Efficacy Treatment in Multiple Sclerosis Is the Best Predictor of Future Disease Activity Over 1 and 2 Years in a Norwegian Population-Based Registry.Frontiers in neurology · 2021Article
- Knowledge Is Power, but Is Ignorance Bliss? Optimising Conversations About Disease Progression in Multiple Sclerosis.Neurology and therapy · 2020Article
- Tumor necrosis factor alpha (TNF-α) and its soluble receptors are associated with disability, disability progression and clinical forms of multiple sclerosis.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2019Article
- BDNF rs6265 polymorphism methylation in Multiple Sclerosis: A possible marker of disease progression.PloS one · 2018Article
- Relation Between the Novel Marker Monocyte to High-Density Lipoprotein Cholesterol Ratio and Severity in Multiple Sclerosis.Annals of Indian Academy of NeurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundEffective therapeutic strategies to preserve function and delay progression in multiple sclerosis (MS) require early recognition of individual disease trajectories.
objectivesTo determine the profiles of disability evolution, identify their early predictors and develop a risk score of increasing disability.
methodsWe analysed demographic, clinical and magnetic resonance imaging (MRI) data from patients with relapsing MS, Expanded Disability Status Scale (EDSS) score of 3.0-4.0 and follow-up ≥ 2 years. Attaining EDSS = 6.0 defined
resultsIn total, 344 out of 542 (63.5%) patients reached EDSS ≥ 6.0; of these, 220 (64.0%) showed disease activity. In patients with activity, the number of relapses before reaching EDSS 3.0-4.0 predicted increasing disability; age > 45 at baseline predicted increasing disability without activity. Combining age and number of relapses increased the risk of and shortened the time to EDSS = 6.0.
conclusionIncreasing disability is frequently associated with persistent activity. The high number of relapses identifies early those patients worsening in the presence of activity. Age predicts increasing disability in the absence of activity. The presence of both factors increases the risk of developing severe disability. As this study likely describes the transition to progression, our findings contribute to improving patient management and stratification in trials on progressive MS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.